IB Net Payout Yields Model

Invest like me - only at Covestor.com

Hims & Hers: Sell-Off Opportunity

By -

  • Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments here » 

Update - July 28, 2023 

Cowen with a bull call on Hims with a price target of $11 after the stock recently traded at $12. Nice the greatest bull call, but it sure beats the short report. 

  • TD Cowen initiated its coverage of the digital healthcare platform Hims & Hers Health (NYSE:HIMS) with an Outperform rating and a $11 per share target on Friday, citing a disconnect between the company’s prospects and the valuation.
  • Noting that Hims & Hers (HIMS) is set to expand at over 78% CAGR in 2019–2023E, analyst Jonna Kim argues that the company’s $1.2B revenue target for 2025, indicating over 22% CAGR, "implies a significant slowdown."

Update - July 13, 2023

Kinda of a joke short report on Hims & Hers today, any stock could face a 25% hit. Heck, we view Apple as having the potential for 50% downside. The stock has bounced off strong support here. 

-Hims & Hers Health (NYSE:HIMS) ticked down 1% amid a new short call from Spruce Point Research.
-Spruce Point sees potential for Hims & Hers (HIMS) shares to fall 25% to 40% to $5.20–$6.50 per share, according to the new report.

Finviz Chart

Original article posted on June 12 

  • Hims & Hers plunged after Q2 adjusted EBITDA guidance disappointed Wall Street.
  • The online health and wellness company has massive growth opportunities ahead and continues investing aggressively in marketing to build its subscriber base.
  • HIMS stock is a bargain below 2x '24 sales targets for a company forecasted to maintain 25% growth while constantly providing conservative estimates.
Despite impressive numbers, Hims & Hers Health (NYSE:HIMS) has dipped the last month. The online health and wellness platform continues to produce the growth most companies can only dream about, but the stock market wants actual

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more

C3.ai: Out Of Steam (Rating Downgrade)

By -
Image
This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Update - June 23, 2023 C3.ai has fallen back to earth after the Investor Day meeting. The Deutsche Bank analyst call on the meeting suggests the company still isn't ready to produce actual numbers from the generative AI demand.  C3.ai ( NYSE: AI ) shares  fell more than 8%  on Friday after investment firm Deutsche Bank reiterated its sell rating on the enterprise software company after it held its investor meeting. Analyst Brad Zelnick said the event "left a lot to be desired" as there were  no details on financials, "limited" updates on the company's operations and investors did not really attend the event, despite it being positioned as for them. "While we appreciate the vast opportunity presented by AI, the event did nothing to ease our skepticism on the true differentiation of the company's platform, its traction with custome
Read more

Archer Aviation: Promising Developments

By -
Image
  Update - June 12, 2023 Archer is finally in the midst of a breakout on the positive FAA news.  -The acting administrator of the Federal Aviation Administration, Billy Nolen, is in talks to join Archer Aviation (NYSE:ACHR), per a report from Reuters. -Citing sources familiar with the situation, the report indicates Nolen will depart his current position atop the FAA in the next few weeks and will then look to transition to a role at Archer (ACHR). Archer’s rival Joby Aviation (JOBY) previously appointed former FAA chief Michael Huerta to a position on its board in March. Original article posted on Jan. 19 This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Archer Aviation Inc. jumped to $3 on the excitement of small insider purchases. The eVTOL manufacturer recently announced several major developments towards FAA certification and production of the Midnight aircraft. Archer Aviation stock is interesting, with a $70
Read more